\News\Home
16-12-2019

Vintura joins forces with PharmaLex in joint venture

The partnership will provide benefits for both organisations. Vintura will be able to access the expertise offered by PharmaLex's global reach in 31 offices across 17 countries, and PharmaLex is set to build on its service portfolio offering to clients with Vintura’s specialisms. The two organisations will continue to operate under their respective, well-established brands.

PharmaLex Group, one of the most experienced and most successful specialist providers of Development Consulting, Regulatory Affairs, Pharmacovigilance, Epidemiology & Risk Management, and Quality Management & Compliance worldwide, has entered into a joint venture with Vintura, based in Amsterdam area in the Netherlands and Munich in Germany.

“We are very excited to be joining forces with the PharmaLex Group”, explains Gérard Klop, Partner at Vintura. “PharmaLex has a very strong heritage in the life sciences sector and we see clear synergies between our two organizations. In addition, the international footprint of PharmaLex supports our international growth objectives”, he adds. “Vintura is an excellent partner for PharmaLex”, Dr. Thomas Dobmeyer, CEO PharmaLex, commented. “Not only do they have significant strategic experience in the life science sector, such as Market Access and product/portfolio strategy, they also service customers outside of our target audience, potentially allowing us to diversify our portfolio”, Thomas adds. “Having an office close to the European Medicines Agency is an additional advantage”.

“Next to building on our mutual strengths and joint opportunities, we are also able to have more impact for our clients and society. Herewith realizing our joint ambition to create sustainable and affordable healthcare with safe and proper patient access to innovation”, both conclude.

About PharmaLex

PharmaLex is one of the largest providers of specialist services for Development Consulting, Regulatory Affairs, Quality Management & Compliance and Pharmacovigilance, Epidemiology and Risk Management worldwide. Our global teams of experts can take you through early strategic planning activities and non-clinical requirements to clinical development, through regulatory submission processes and finally guide you to market approval and product maintenance post-launch activities. We strive to deliver exceptional results — going above and beyond the standard to deliver tailor-made solutions. We aim to exceed your expectations and live by our values – flexibility, efficiency, passion and dedication.

The PharmaLex Group now has over 950 employees, with 31 offices in 17 countries and more than 600 satisfied clients worldwide.

About Vintura

Vintura is a leading strategy & organization consultancy company specialized in healthcare and life sciences, founded in 2000. We apply our extensive expertise and experience to support healthcare providers, payers and pharmaceuticals and medical devices companies to bring about ongoing improvement based on a clear vision and solid strategy. Vintura operates both on a European and local level, working for EMEA HQs and associations as well as local healthcare organizations and affiliates, herewith taking into account local healthcare systems dynamics.

We work with our clients to arrive at smart and effective solutions. Our mission is ‘creating meaningful impact in healthcare together’. We do so based on our core values: being ambitious and brave in finding the best solutions while being emphatic and sincere to create maximal commitment.

Vintura consists of 30+ dedicated professionals and has offices in the Netherlands and Germany and is currently further expanding into Europe.  We have a long-standing track record of satisfied clients, with an average NPS score of 8,8.

For further information, please contact:

Mrs. Laila Vernooij
Manager Marketing & Communication
lvernooij@vintura.com, +31 6 12 67 20 94

Ms. Eva Keck
PharmaLex GmbH; Director, Business Development Operations
eva.keck@pharmalex.com, +49 621 18 15 38 0

Share
For further information, please contact me.